BioCryst Pharmaceuticals Inc (BCRX) (Q3 2026) Earnings Call Highlights: ORLADEYO Revenue Climbs ...
BioCryst Pharmaceuticals Inc (BCRX) posted $174.8 million in ORLADEYO net revenue, $86 million in non-GAAP operating profit, and raised its 2026 total revenue guidance to $715 million to $730 million. Related Stocks: BCRX ,